AI has an image problem . And one way to fix it is for top companies to dive headlong into health care. Why it matters: Saving the world with AI-designed cures is better than being blamed for ruining the environment or driving up Americans' utility bills. - But even the most advanced AI models can't produce miracle treatments at the moment — and could create serious security risks if they try. - That could set up a fraught debate over the next two or three years about the allocation of resources and whether the benefits of throwing vast amounts of computing capacity into medical research outweigh the costs. Driving the news: The Wall Street Journal reported this month that Anthropic was trying to shore up investor confidence ahead…
The Rouche test was developed in collaboration with Eli Lilly and is intended for people 55 years and older with “signs, symptoms, or complaints of cognitive decline.”
Data: Bureau of Labor Statistics; Chart: Courtenay Brown/Axios America is experiencing its biggest prescription drug price deflation in generations. Why it matters: By one important measure, there is a striking reversal underway for one of health care's most stubbornly expensive necessities amid a major Washington push to lower drug costs. By the numbers: Prescription drug prices fell 0.8% in July and are down 3.1% from a year ago — the steepest annual decline in more than six decades, according to the recent Consumer Price Index . - Prices haven't risen in any month this year, an unusually persistent stretch of flat or falling drug prices. - The downward trend comes as costs for hospital and physician services continue to rise. The…
Medicare's first-of-its-kind weight-loss drug program has officially launched, giving American seniors access to GLP-1 drugs at a subsidized cost.
Medicare’s new weight-loss drug program offers affordable access to GLP-1 medication for seniors, marking a significant shift in healthcare coverage and efforts to combat obesity . PULSE POINTS WHAT HAPPENED: Medicare’s first-of-its-kind weight-loss drug program has officially launched, giving American seniors access to GLP-1 drugs at a subsidized cost. DETAIL: On Wednesday, Medicare & Medicaid Services launched a new program allowing Americans aged 65 and older to access weight-loss drugs at a reduced cost of $50 a month, starting with an 18-month trial period. This is the first time Medicare has offered coverage for GLP-1 weight-loss drugs, such as Novo Nordisk’s Wegovy and Eli Lilly’s Foundayo and Zepbound. Previously,…Open
